Portfolio and pipeline
Multiparticulate pellet formulations.
Semi-finished, ready-to-fill pellet dosage forms. Search by molecule, or separate commercial manufacture from the development pipeline.
Loading the portfolio…
Portfolio and pipeline
Semi-finished, ready-to-fill pellet dosage forms. Search by molecule, or separate commercial manufacture from the development pipeline.
Loading the portfolio…
Showing 38 validated formulations
Active Molecule: Omeprazole
Gastro-resistant enteric coated pellets formulated for hard gelatin capsule filling. Features a protective sub-coat barrier and enteric polymer membrane designed to protect the acid-labile active substance in gastric fluid and release it in intestinal conditions.
Validated drug load
7.5% w/w
Standards: IP · USP · BP
Active Molecule: Pantoprazole Sodium
Gastro-resistant enteric coated pellets formulated with a protective sub-coat barrier to protect the active substance before functional enteric polymer coating.
Validated drug load
15.0% w/w
Standards: IP · USP · BP
Active Molecule: Rabeprazole Sodium
Enteric coated pellets engineered with protective barrier sub-coating and enteric polymer layering for capsule formulations.
Validated drug load
7.5% w/w
Standards: IP · USP
Active Molecule: Itraconazole
Immediate-release pellets of Itraconazole layered onto neutral starter sugar spheres with a protective seal coating for capsule filling.
Validated drug load
22.5% w/w
Standards: IP · USP · BP
Active Molecule: Domperidone
Sustained-release multiparticulates coated with a functional diffusion membrane to achieve extended drug release across gastrointestinal transit.
Validated drug load
30.0% w/w
Standards: IP · USP · BP
Active Molecule: Domperidone
Immediate-release pellets formulated for prompt drug dissolution, suitable for capsule filling or multi-component combination capsule fills.
Validated drug load
10.0% w/w
Standards: IP · BP
Active Molecule: Atorvastatin
Immediate-release pellets containing Atorvastatin, formulated with protective barrier coating for capsule filling.
Validated drug load
10.0% w/w
Standards: IP · USP · BP
Active Molecule: Clopidogrel
High drug-load (50% w/w) immediate-release antiplatelet multiparticulates layered onto neutral starter cores for capsule filling.
Validated drug load
50.0% w/w
Standards: IP · USP · BP
Active Molecule: Rosuvastatin
Immediate-release pellets containing Rosuvastatin, layered with protective coatings to maintain active substance stability and batch content uniformity.
Validated drug load
10.0% & 7.5% w/w
Standards: IP
Active Molecule: Dried Ferrous Sulphate 150mg, Folic Acid 0.5mg, Zinc Sulphate 61.8mg
Triple-nutrient combination pellet formulation engineered with separating barrier layers for multiparticulate capsule filling.
Validated drug load
Dried FeSO4 150mg, Folic Acid 0.5mg, Zinc Sulphate 61.8mg
Standards: IP / Food Grade Standards
Active Molecule: Ferrous Fumarate 152mg IR, Zinc Sulphate Monohydrate 15mg IR, Folic Acid 1.5mg IR & Vitamin B12 15mcg
Multi-component combination pellet formulation manufactured with barrier film layers to support component stability in blended capsule fills.
Validated drug load
Ferrous Fumarate 152mg, ZnSO4 Monohydrate 15mg, Folic Acid 1.5mg, B12 15mcg
Standards: IP / Nutritional Standards
Active Molecule: Sucrose & Starch Neutral Starter Core
Neutral sugar spheres manufactured with dedicated equipment and manpower on the first floor of the facility. Sized across multiple sieve fractions for fluid-bed drug layering and film coating.
Validated drug load
Neutral Inert Starter Core
Standards: IP · BP · USP · Ph. Eur.
Active Molecule: Neutral Placebo Excipient Matrix
Neutral dummy pellets manufactured with dedicated equipment and manpower. Used as volumetric fill modulators in capsule filling and as process validation substrates.
Validated drug load
Neutral Placebo Core
Standards: In-house Specification
Active Molecule: Esomeprazole Magnesium
Enteric coated pellets under development pipeline for gastro-resistant proton pump inhibition.
Validated drug load
8.5%, 10.0%, 15.0%, 20.0%, 22.0% & 22.5% w/w
Standards: IP / USP Candidate
Active Molecule: Dexlansoprazole
Dual delayed-release multiparticulate technology in development pipeline.
Validated drug load
20.0% & 22.5% w/w
Standards: In-house Development Specification
Active Molecule: Dabigatran Etexilate Mesylate
Immediate release multiparticulate pellets under development pipeline.
Validated drug load
35.0% & 40.0% w/w
Standards: USP / In-house
Active Molecule: Duloxetine Hydrochloride
Enteric coated multiparticulates formulated with an acid-protective enteric shell under development pipeline.
Validated drug load
17.0%, 20.0% & 22.5% w/w
Standards: USP / IP Candidate
Active Molecule: Tamsulosin Hydrochloride
Micro-dose sustained release multiparticulates with membrane diffusion coating under development pipeline.
Validated drug load
0.2%, 0.4%, 0.12% & 0.16% w/w
Standards: IP / USP Candidate
Active Molecule: Venlafaxine Hydrochloride
Extended release multiparticulates utilizing membrane diffusion barriers under development pipeline.
Validated drug load
32.0%, 33.0%, 36.0% & 40.0% w/w
Standards: USP / IP Candidate
Active Molecule: Itopride Hydrochloride
Sustained release pellets under development pipeline.
Validated drug load
60.0% w/w
Standards: In-house Specification
Active Molecule: Diclofenac Sodium
Sustained release multiparticulate pellets with diffusion barrier coating under development pipeline.
Validated drug load
35.0%, 40.0% & 50.0% w/w
Standards: IP / BP Candidate
Active Molecule: Mebeverine Hydrochloride
Sustained release pellets with diffusion barrier coating under development pipeline.
Validated drug load
40.0%, 50.0% & 80.0% w/w
Standards: BP / IP Candidate
Active Molecule: Lansoprazole
Gastro-resistant enteric coated pellets for proton pump inhibition.
Validated drug load
8.5%, 9.5%, 11.2%, 12.5% & 22.5% w/w
Standards: USP / IP Candidate
Active Molecule: Orlistat
Immediate release pellets under development pipeline.
Validated drug load
25.0% & 50.0% w/w
Standards: USP Candidate
Active Molecule: Chlorpheniramine Maleate
Antihistamine multiparticulates formulated for combination products under development.
Validated drug load
4.0% w/w
Standards: IP Candidate
Active Molecule: Ketoprofen
Sustained-release NSAID multiparticulates under development pipeline.
Validated drug load
60.0% w/w
Standards: BP / IP Candidate
Active Molecule: Levosulpiride
Sustained release pellets under development pipeline for gastrointestinal motility blends.
Validated drug load
40.0% w/w
Standards: In-house Specification
Active Molecule: Sucralfate
High drug-load immediate release pellets under development pipeline.
Validated drug load
70.0% w/w
Standards: USP / IP Candidate
Active Molecule: Atorvastatin (10mg/20mg) & Clopidogrel Bisulphate (75mg)
Cardiovascular dual-drug multiparticulates combining antiplatelet and statin pellets into a single capsule fill.
Validated drug load
10mg/75mg & 20mg/75mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Esomeprazole EC (20mg/40mg) & Domperidone SR (30mg)
Gastro-resistant PPI with sustained-release prokinetic multiparticulates for capsule filling under development.
Validated drug load
20mg/30mg & 40mg/30mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Pantoprazole Sodium EC (20mg/40mg) & Domperidone SR (30mg)
Stabilized enteric pantoprazole combined with sustained release domperidone pellets under development.
Validated drug load
20mg/30mg & 40mg/30mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Pantoprazole EC (40mg) & Itopride HCl SR (150mg)
Enteric coated proton pump inhibitor combined with sustained release prokinetic pellets under development.
Validated drug load
40mg/150mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Pantoprazole EC (40mg) & Levosulpiride SR (75mg)
Enteric coated PPI combined with sustained-release prokinetic multiparticulates under development.
Validated drug load
40mg/75mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Rabeprazole Sodium EC (20mg) & Domperidone SR (30mg)
Enteric PPI blended with sustained release antiemetic pellets for capsule filling under development.
Validated drug load
20mg/30mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Rabeprazole Sodium EC (20mg) & Aceclofenac SR (100mg/200mg)
Gastro-protected NSAID dual system designed to mitigate ulcerogenic risks of chronic anti-inflammatory therapy.
Validated drug load
20mg/100mg & 20mg/200mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Rabeprazole Sodium EC (20mg) & Levosulpiride SR (75mg)
Enteric rabeprazole combined with sustained levosulpiride multiparticulates.
Validated drug load
20mg/75mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Rabeprazole Sodium EC (20mg) & Itopride HCl SR (150mg)
Prokinetic and PPI dual multiparticulates in fixed-ratio capsule fills.
Validated drug load
20mg/150mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Tamsulosin HCl SR (0.4mg) & Dutasteride IR (0.5mg)
Urological combo multiparticulates uniting alpha-blocker sustained release with 5-alpha reductase inhibitor.
Validated drug load
0.4mg/0.5mg dose equivalent
Standards: In-house B2B Standard